AGENTIX Discusses 2022 Clinical Development Efforts and Potential Uplisting with The Stock Day Podcast

<div>The Stock Day Podcast welcomed AGENTIX (AGTX)(“the Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of metabolic diseases including type 2 diabetes mellitus, chronic obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). CEO of the Company, Rudy Mazzocchi, joined Stock Day host Everett Jolly. </div>